BAC

Bank of America

$51.14

+0.57%
Oct 29, 2026
Bobby Quantitative Model
Bank of America Corporation is one of the largest diversified financial institutions in the United States, operating a roughly $3.5 trillion balance sheet across four segments: consumer banking, global wealth and investment management, global banking, and global markets. The firm is a cornerstone of the U.S. financial system, holding the second-largest domestic deposit market share, the fourth-largest global trading operation, and a top-four investment banking franchise, giving it a scale-driven, rate-sensitive earnings profile distinct from pure fee-based or pure trading peers. The current investor narrative centers on the durability of net interest income after management raised 2027 NII guidance, the strength of its low-cost deposit franchise, and the absorption of previously disclosed settlement costs, all set against a Q3 earnings miss and a regulatory fine that triggered a sharp single-day sell-off in mid-October. Broader macro crosscurrents — sticky 3.7% inflation reviving Fed hike risk and a historically stretched Buffett Indicator reading of 239% — have added a valuation and rate-sensitivity debate on top of the company-specific story, while a 14% dividend increase reinforces the income case.

People also watch

JPMorgan Chase

JPMorgan Chase

JPM

Analysis
Wells Fargo

Wells Fargo

WFC

Analysis
Citigroup

Citigroup

C

Analysis
Franklin International Core Dividend Tilt Index ETF

Franklin International Core Dividend Tilt Index ETF

DIVI

Analysis
Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

LABU

Analysis

BobbyInvestment Opinion: Should I buy BAC Today?

Rating: Buy (accumulate on weakness). The core thesis is that BAC's forward PE of 9.74x and PEG of 0.73 price in excessive pessimism relative to a strong_buy consensus (mean 1.48) and an average target of $62.95, implying 24.5% upside from $50.56. The mid-October sell-off on a Q3 earnings miss and regulatory fine appears overdone given the raised 2027 NII guidance and intact deposit franchise.

Supporting evidence: (1) forward PE of 9.74x versus trailing 14.18x implies meaningful EPS growth toward the $6.82 consensus; (2) revenue grew 5.84% YoY to $49.393 billion in Q2 2026; (3) net margin expanded to 18.37% from 15.25% and gross margin to 61.13% from 53.30%; (4) TTM free cash flow of $94.742 billion comfortably funds the 2.36% dividend (31.3% payout) and buybacks; (5) the $62.95 average target implies 24.5% upside, with even the $56.00 low target 10.7% above the current price.

Key risks that could invalidate the thesis: a renewed inflation spike forcing Fed hikes that compress NII and credit quality; a break below the $46.12 52-week low triggering further technical selling; and P/B at 1.34x near the top of its historical range limiting multiple expansion. The rating would upgrade to Strong Buy if the stock stabilizes above $55 with NII guidance reaffirmed, and downgrade to Hold if it breaks below $46.12 or if 2027 NII guidance is cut. Valuation verdict: fairly valued to modestly undervalued on a forward basis, but not distressed on a P/B basis — the stock is cheap relative to growth, not relative to book.

Sign up to view all

BAC 12-Month Price Forecast

The forward-looking view is bullish with medium confidence: BAC's valuation (9.74x forward PE, 0.73 PEG) and analyst consensus (strong_buy, $62.95 target) suggest the mid-October sell-off is overdone, while margin expansion and raised 2027 NII guidance support earnings durability. However, the technical downtrend (-18.52% over three months, -21.37% relative strength) and sticky inflation at 3.7% warrant caution, as a break below $46.12 would invalidate the thesis. I would upgrade to high confidence if the stock stabilizes above $55 with NII guidance reaffirmed, and downgrade to neutral if it breaks below $46.12 or if Q4 earnings show further margin compression.

Historical Price
Current Price $51.14
Average Target $59.50
High Target $71.00
Low Target $46.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Bank of America's 12-month outlook, with a consensus price target around $62.95 and implied upside of +23.1% versus the current price.

Average Target

$62.95

0 analysts

Implied Upside

+23.1%

vs. current price

Analyst Count

—

covering this stock

Price Range

$56 - $71

Analyst target range

Coverage is broad and conviction is high, with 22 analysts and a consensus recommendation of strong_buy (mean rating 1.48 on a 1-to-5 scale). The average target price of $62.95 implies roughly 24.5% upside from the current $50.56, a wide gap that reflects the disconnect between the recent sell-off and fundamental expectations. Consensus leans decisively bullish, supported by a cluster of reiterated Outperform/Overweight ratings from JP Morgan, UBS, Evercore ISI, Wells Fargo, RBC, Barclays, Truist, and Keefe Bruyette & Woods through July and August 2026, with only Baird maintaining a Neutral stance. The target range of $56.00 to $71.00 is moderately wide — a 26.8% spread from low to high — signaling meaningful uncertainty around the rate path and credit outlook. The $71.00 high target assumes multiple expansion and successful execution on the raised 2027 NII guidance, likely requiring a stabilization in rates and clean credit metrics, while the $56.00 low still implies about 10.7% upside and prices in margin compression or further regulatory costs. Notably, even the low target sits above the current price, indicating analysts view the mid-October plunge as overdone; the absence of any downgrades despite the earnings miss and fine reinforces that the institutional consensus remains constructive, though the wide spread warrants position-sizing discipline given the stock's 1.21 beta.

Drowning in data?

Find the real signal!

Bulls vs Bears: BAC Investment Factors

The bear case currently has stronger near-term technical evidence: BAC is in a clear downtrend, down 18.52% over three months with -21.37% relative strength versus SPY, and the mid-October earnings miss and regulatory fine created a fresh catalyst-driven breakdown. However, the bull case rests on more durable fundamental evidence: forward PE of 9.74x, PEG of 0.73, expanding margins (net margin 18.37% vs. 15.25% a year ago), raised 2027 NII guidance, and a strong_buy consensus with a $62.95 average target implying 24.5% upside. The single most important tension is whether the raised 2027 NII guidance can be delivered against a sticky-inflation, Fed-hike-risk backdrop — if NII proves durable, the valuation gap closes; if rate pressure compresses margins, the downtrend extends toward the $46.12 low.

Bullish

  • Analyst consensus strong buy with 24.5% upside: 22 analysts rate BAC a strong_buy (mean 1.48) with an average target of $62.95, implying 24.5% upside from $50.56. Even the lowest target of $56.00 sits 10.7% above the current price, suggesting the mid-October sell-off is viewed as overdone.
  • Forward PE below 10x signals deep value: The forward PE of 9.74x versus trailing 14.18x reflects expected EPS expansion toward the $6.82 consensus estimate. A PEG of 0.73 indicates the stock trades at a discount to its growth rate, a classic value signal for a money-center bank.
  • Margin expansion and profitability improving: Q2 2026 net margin rose to 18.37% from 15.25% a year earlier, while gross margin expanded to 61.13% from 53.30% and operating margin improved to 23.41% from 16.47%. Net income grew to $9.074 billion from $7.116 billion, demonstrating strong operating leverage.
  • Raised 2027 NII guidance and deposit franchise: Management raised 2027 net interest income guidance, underpinned by the second-largest U.S. deposit market share. Q2 2026 revenue of $49.393 billion grew 5.84% YoY, and the diversified four-segment model (Global Markets $7.109B, Consumer Banking $11.049B, GWIM $6.712B, Global Banking $6.287B) reduces concentration risk.

Bearish

  • Severe relative underperformance and downtrend: BAC is down 18.52% over three months and 9.71% over one month, versus SPY gains of 2.85% and -1.02% respectively, producing relative strength of -21.37% and -8.69%. The stock sits at just 23.2% of its 52-week range ($46.12–$65.23), signaling institutional distribution and a damaged chart.
  • Q3 earnings miss and regulatory fine: The mid-October Q3 earnings miss and a regulatory fine triggered a sharp single-day sell-off, with the stock falling from $53.96 on October 13 to $51.39 on October 14. This event-driven breakdown raises questions about near-term earnings quality and compliance costs.
  • Sticky inflation revives Fed hike risk: Inflation at 3.7% has revived expectations of further Fed tightening, which pressures bank valuations through credit concerns and potential NII compression if deposit costs rise faster than asset yields. The Buffett Indicator at a record 239% also signals broad equity overvaluation, increasing sector rotation risk.
  • P/B near top of historical range: At 1.34x price-to-book, BAC trades near the top of its 2023–2026 range of roughly 0.76x to 1.35x, suggesting book value is not cheap relative to history even after the drawdown. This tempers the value case and implies the market is pricing reasonable but not distressed expectations.

BAC Technical Analysis

Bank of America is in a clear intermediate-term downtrend despite a modestly positive longer-term base, with the stock down 2.32% over the past year and sitting at $50.56, which places it at roughly 23.2% of its 52-week range of $46.12 to $65.23. That positioning near the lower third of the annual band signals the stock is closer to a value/oversold zone than to momentum-driven overextension, but the persistent drift lower argues against calling a bottom prematurely. The 22.25% max drawdown confirms a meaningful correction has already occurred, and the failure to hold the mid-year highs near $64.81 leaves the chart structurally damaged. Short-term momentum is decisively negative and accelerating: the stock is down 9.71% over one month and 18.52% over three months, a sharp deceleration from the roughly flat six-month change of -2.86% and the -9.63% YTD decline. This 1-month versus 1-year divergence — with the recent leg far weaker than the annual trend — points to a fresh catalyst-driven breakdown rather than simple mean reversion, consistent with the mid-October earnings miss and regulatory fine. Relative strength is deeply negative across every window, with -8.69% versus SPY over one month and -21.37% over three months while the S&P gained 2.85%, indicating institutional distribution and clear underperformance. Key support sits at the 52-week low of $46.12, roughly 8.8% below the current price; a breakdown there would signal capitulation and likely force another leg lower, while resistance at the $65.23 high is 29% above and would require a full trend reversal to challenge. With a beta of 1.214, the stock carries roughly 21% more volatility than the market, meaning position sizing should account for amplified drawdowns — a 1% SPY decline implies roughly a 1.2% BAC move — and the elevated short ratio of 2.32 suggests some bearish positioning that could fuel a squeeze on any positive catalyst.

Beta

1.21

1.21x market volatility

Max Drawdown

-22.3%

Largest decline past year

52-Week Range

$46-$65

Price range past year

Annual Return

-2.7%

Cumulative gain past year

PeriodBAC ReturnS&P 500
1m-7.0%+0.7%
3m-17.4%+3.0%
6m-3.9%+6.8%
1y-2.7%+11.9%
ytd-8.6%+12.8%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

BAC Fundamental Analysis

Revenue is growing at a solid clip, with Q2 2026 revenue of $49.393 billion up 5.84% year over year from $46.666 billion in Q2 2025, and the multi-quarter trend shows steady sequential expansion from $47.886 billion in Q1 2026 and $49.691 billion in Q4 2025. Segment data shows a balanced franchise: Global Markets at $7.109 billion and Consumer Banking at $11.049 billion lead, followed by Global Wealth and Investment Management at $6.712 billion and Global Banking at $6.287 billion, indicating no single segment is carrying the whole company. The growth trajectory supports the raised 2027 NII guidance narrative, though the 5.84% YoY pace is moderate for a money-center bank and leaves earnings sensitive to rate-path shifts. Profitability is robust and improving: Q2 2026 net income reached $9.074 billion with a net margin of 18.37%, up from $7.116 billion and a 15.25% margin in Q2 2025, while gross margin expanded to 61.13% from 53.30% a year earlier. Operating margin of 23.41% in Q2 2026 compares favorably to 16.47% in the prior-year quarter, and the TTM net margin of 15.93% with a 56.08% gross margin is consistent with a well-run diversified bank. The margin expansion reflects both revenue growth and cost discipline, with Q2 2026 operating expenses of $18.627 billion against $37.828 billion in total costs, though the Q3 earnings miss and regulatory fine suggest some near-term margin noise. Balance sheet and cash flow metrics reflect a leveraged financial institution: debt-to-equity of 1.21, a current ratio of 0.417, and ROE of 10.06% with a thin ROA of 0.94% are typical for banking but leave limited cushion. TTM free cash flow of $94.742 billion is substantial, and Q2 2026 operating cash flow of $29.043 billion comfortably funded $6.006 billion of buybacks and $2.33 billion of dividends, while the 2.36% dividend yield with a conservative 31.3% payout ratio signals ample capital return capacity. The company generates enough internal cash to fund growth and returns, though the low current ratio and $229.745 billion cash position against a $3.5 trillion balance sheet mean liquidity management remains a core operating discipline.

Quarterly Revenue

$49.4B

2026-06

Revenue YoY Growth

+5.8%

YoY Comparison

Gross Margin

61.1%

Latest Quarter

Free Cash Flow

$94.7B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Consumer Banking Segment
Global Wealth and Investment Management Segment
Global Banking Segment
Global Markets Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is BAC Overvalued?

Because Bank of America is solidly profitable — Q2 2026 net income of $9.074 billion and positive TTM earnings — the PE ratio is the appropriate primary metric, and the trailing PE of 14.18x against a forward PE of 9.74x implies the market expects meaningful earnings growth, with the 31.3% compression between the two multiples reflecting consensus EPS expansion toward the $6.82 average estimate. The forward multiple below 10x is inexpensive in absolute terms and suggests the market is discounting either rate-driven NII pressure or credit concerns. On a peer basis, the 1.34x price-to-book and 2.11x price-to-sales sit at modest levels for a money-center bank, and the 0.73 PEG ratio — well below 1.0 — indicates the stock trades at a discount to its growth rate, a classic value signal. The 13.48x EV/EBITDA and 1.16x EV/Sales are low relative to the broader market, consistent with the sector's structural discount, and the 2.36% dividend yield with a 31.3% payout provides income support that partially offsets the valuation discount. Historically, the current 14.18x trailing PE sits above the 11.68x recorded in Q2 2026 and the 10.88x in Q1 2026, but below the 23.38x seen in Q4 2023, placing it in the middle-to-upper portion of its recent band even as the price has fallen — a function of the low $0.075 reported EPS base distorting the trailing figure. The 1.34x P/B is near the top of its 2023–2026 range of roughly 0.76x to 1.35x, suggesting book value is not cheap relative to history even after the drawdown, which tempers the value case and implies the market is pricing in reasonable but not distressed expectations.

PE

14.2x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 8x~14x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

13.5x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on the bank's leveraged balance sheet and earnings sensitivity to rate paths. Debt-to-equity of 1.21 and a current ratio of 0.417 leave limited liquidity cushion, while ROA of 0.94% and ROE of 10.06% are modest, meaning small margin changes have outsized earnings impact. The Q3 earnings miss and regulatory fine introduce near-term margin noise, and the $0.075 reported EPS base distorts trailing valuation, making it harder to assess true earnings power. Revenue growth of 5.84% YoY is moderate for a money-center bank and leaves earnings sensitive to any deceleration in net interest income.

Market and competitive risks include valuation compression and sector rotation. At 1.34x P/B, BAC sits near the top of its 2023–2026 range of 0.76x–1.35x, so book value is not cheap relative to history even after the 22.25% max drawdown. The stock's beta of 1.214 means it carries roughly 21% more volatility than the market, amplifying drawdowns in risk-off environments. Sticky 3.7% inflation reviving Fed hike risk and a record 239% Buffett Indicator reading increase the probability of multiple compression across financials, while the -21.37% three-month relative strength versus SPY signals active institutional distribution.

Worst-case scenario: a renewed inflation spike forces additional Fed hikes, deposit costs rise faster than asset yields, and 2027 NII guidance is cut, triggering analyst downgrades and a break below the 52-week low of $46.12. From the current $50.56, that represents roughly -8.8% downside to the 52-week low, and a capitulation break could extend toward the $46 area or lower, implying a total drawdown of 10–15% from current levels. The analyst low target of $56.00 actually sits above the current price, so the true bear case is technical rather than fundamental — a sustained break below $46.12 would invalidate the value thesis and likely force another leg lower.

FAQ

The most severe risk is rate-driven margin compression: sticky 3.7% inflation reviving Fed hike risk could raise deposit costs faster than asset yields, pressuring the raised 2027 NII guidance and triggering analyst downgrades. Second is technical breakdown risk: the stock is at 23.2% of its 52-week range and a break below $46.12 would signal capitulation, with roughly -8.8% downside from current levels and potential for further selling. Third is regulatory and earnings risk: the mid-October Q3 earnings miss and regulatory fine created a fresh catalyst-driven breakdown, and further fines or a Q4 miss would extend the downtrend. Fourth is valuation compression risk: at 1.34x P/B near the top of its historical range, the stock has limited multiple expansion cushion, and a record 239% Buffett Indicator reading increases broad equity correction risk.

The 12-month forecast has three scenarios: a bull case (30% probability) targeting $65–$71 if rates stabilize and 2027 NII guidance is delivered, a base case (50% probability) targeting $56–$63 toward the $62.95 analyst average as the sell-off proves overdone, and a bear case (20% probability) targeting $46–$56 if Fed hikes compress margins and the stock breaks below $46.12. The base case is most likely, with the key assumption being that 2027 NII guidance is delivered within a reasonable range without further regulatory fines or credit deterioration. The strong_buy consensus (mean 1.48) and $62.95 average target anchor the base case, while the $56.00 low target provides a floor above the current price.

BAC appears modestly undervalued on a forward basis but fairly valued on a book basis. The forward PE of 9.74x is inexpensive in absolute terms and well below the trailing 14.18x, implying the market expects meaningful EPS growth toward the $6.82 consensus. The PEG of 0.73 is below 1.0, a classic value signal, and the 2.11x price-to-sales and 13.48x EV/EBITDA are low relative to the broader market. However, the 1.34x price-to-book sits near the top of its 2023–2026 range of 0.76x–1.35x, suggesting book value is not cheap relative to history. The market is pricing in reasonable but not distressed expectations — the valuation implies the market expects NII durability but discounts rate-driven pressure and credit concerns.

From a risk/reward perspective, BAC offers a favorable setup for patient investors: the forward PE of 9.74x and PEG of 0.73 suggest the stock is cheap relative to growth, while the strong_buy consensus and $62.95 average target imply 24.5% upside from $50.56. The biggest downside risk is a break below the $46.12 52-week low, which would represent roughly -8.8% from current levels and could trigger further selling. The stock is down 18.52% over three months with -21.37% relative strength versus SPY, so near-term momentum is negative, but the mid-October sell-off on a Q3 earnings miss and regulatory fine appears overdone given raised 2027 NII guidance. It is a good buy for value and income investors with a 12–18 month horizon who can tolerate volatility (beta 1.214), but not for short-term traders given the damaged chart.

BAC is better suited for long-term holding (minimum 12–18 months) than short-term trading. The stock is in a clear intermediate-term downtrend with -18.52% three-month performance and -21.37% relative strength versus SPY, making short-term momentum trading risky. However, the 2.36% dividend yield with a conservative 31.3% payout ratio and 14% recent dividend increase provides income support, while the forward PE of 9.74x and PEG of 0.73 offer value upside for patient investors. The beta of 1.214 means the stock carries roughly 21% more volatility than the market, so position sizing should account for amplified drawdowns. A suggested minimum holding period of 12–18 months allows time for the NII guidance narrative to play out and for the technical downtrend to reverse.